Organon & Co | OGN - Equity Capital And Reserves


Organon & Co reported $903M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Celltrion KRW 434.82B 1.14B Mar/2026
Cspc Pharmaceutical CNY 33.18B 71.46M Dec/2025
Deva Holding AS TRY 5.79B 604.07M Sep/2023
Dianthus Therapeutics USD 1.17B 29.29M Jun/2026
Divis Laboratories Ltd INR 167.61B 13.48B Mar/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Kangmei Pharma CNY 7.31B 84.82M Mar/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
Laboratorios Farma EUR 539.39M 22.74M Dec/2023
Malin Corporation EUR 193.2M 75M Dec/2024
Medical Developments International AUD 54.77M 335K Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Neuren Pharmaceuticals AUD 338.45M 15.18M Dec/2025
Novartis USD 38.93B 7.2B Mar/2026
Organigram Holdings CAD 371.81M 2.36M Mar/2026
Organon & Co USD 903M 151M Mar/2026
Ovoca Bio EUR 780K 485K Dec/2025
Pharma Mar EUR 250.77M 1.1M Jun/2026
Qiagen NV USD 3.33B 446.45M Mar/2026
Sartorius EUR 2.82B 96.3M Jun/2026
Sino Biopharmaceutical CNY 34B 1.48B Jun/2025
Tilray USD 1.58B 39.08M Sep/2025
Zealand Pharma A/S 14.47B 361.61M Mar/2026